Improving quality of life through innovations in urology.
Urovant Sciences
Vibegron
Our lead product candidate, vibegron, is an investigational oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS).
Latest News
The latest posts and articles
-
Urovant Sciences Reports 2019 Third Fiscal...
on February 13, 2020
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Feb. 13, 2020-- Urovant Sciences […]
Read Latest Post -
Urovant Sciences to Report 2019 Third Fiscal...
on February 6, 2020
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Feb. 6, 2020-- Urovant Sciences (Nasdaq: […]
Read Latest Post -
Urovant Sciences Announces Publication of...
on February 4, 2020
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Feb. 4, 2020-- Urovant Sciences (Nasdaq: […]
Read Latest Post
View more
Copyright 2018 © All Rights Reserved